- Report
- April 2025
- 175 Pages
Global
From €3970EUR$4,490USD£3,437GBP
- Report
- April 2025
- 250 Pages
Global
From €3970EUR$4,490USD£3,437GBP
- Report
- April 2025
- 175 Pages
Global
From €3970EUR$4,490USD£3,437GBP
- Report
- March 2025
- 200 Pages
Global
From €3970EUR$4,490USD£3,437GBP
- Report
- March 2025
- 200 Pages
Global
From €3970EUR$4,490USD£3,437GBP
- Report
- February 2025
- 200 Pages
Global
From €3970EUR$4,490USD£3,437GBP
- Report
- February 2025
- 200 Pages
Global
From €3970EUR$4,490USD£3,437GBP
- Report
- February 2025
- 200 Pages
Global
From €3970EUR$4,490USD£3,437GBP
- Report
- January 2025
- 175 Pages
Global
From €3970EUR$4,490USD£3,437GBP
- Report
- August 2025
Global
From €4333EUR$4,900USD£3,751GBP
- Report
- July 2025
Global
From €4333EUR$4,900USD£3,751GBP
- Report
- June 2025
- 120 Pages
Global
From €4333EUR$4,900USD£3,751GBP
- Report
- April 2025
Global
From €4333EUR$4,900USD£3,751GBP
- Report
- August 2025
- 287 Pages
Global
From €5173EUR$5,850USD£4,478GBP
- Report
- September 2025
- 182 Pages
Global
From €5173EUR$5,850USD£4,478GBP
- Report
- September 2025
- 564 Pages
Global
From €5173EUR$5,850USD£4,478GBP
- Report
- September 2025
- 276 Pages
Global
From €5173EUR$5,850USD£4,478GBP
- Report
- September 2025
- 413 Pages
Global
From €5173EUR$5,850USD£4,478GBP
- Report
- August 2025
- 189 Pages
Global
From €3135EUR$3,545USD£2,714GBP
€3483EUR$3,939USD£3,015GBP
- Report
- April 2025
- 200 Pages
Global
From €7029EUR$7,950USD£6,086GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more